UK's NICE Rejects US Industry Attack On Its HTA Methods
The National Institute for Health and Care Excellence does not agree with assertions by the US pharmaceutical industry that its HTA process are “rigid” and “fail to recognize the full value of innovative medicines.”
You may also be interested in...
The US has published its final negotiating objectives for a post-Brexit trade deal with the UK, which include pushing for stronger IP protections and changes to UK processes for patient access to new drugs.
US industry lobby group PhRMA wants a future post-Brexit US-UK trade deal to lengthen regulatory data protection for biologicals and to introduce stronger patent protections in the UK. The generics and biosimilars industry has rejected PhRMA's proposals, saying they would delay the launch of competing products in the UK and have a knock-on effect on biologic drug pricing in the US.
The monkeypox cases reported this month are evidence of chains of transmission of the virus, according to the European Centre for Disease Prevention and Control, which says that vaccination of high-risk close contacts should be considered after a benefit-risk assessment.